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Abstract: Selective laser sintering (SLS) is a rapid prototyping technique for the production of three-
dimensional objects through selectively sintering powder-based layer materials. The aim of the 
study was to investigate the effect of energy density (ED) and formulation factors on the printability 
and characteristics of SLS irbesartan tablets. The correlation between formulation factors, ED, and 
printability was obtained using a decision tree model with an accuracy of 80%. FT-IR results re-
vealed that there was no interaction between irbesartan and the applied excipients. DSC results 
indicated that irbesartan was present in an amorphous form in printed tablets. ED had a significant 
influence on tablets’ physical, mechanical, and morphological characteristics. Adding lactose mon-
ohydrate enabled faster drug release while reducing the possibility for printing with different laser 
speeds. However, formulations with crospovidone were printable with a wider range of laser 
speeds. The adjustment of formulation and process parameters enabled the production of SLS tab-
lets with hydroxypropyl methylcellulose with complete release in less than 30 min. The results sug-
gest that a decision tree could be a useful tool for predicting the printability of pharmaceutical for-
mulations. Tailoring the characteristics of SLS irbesartan tablets by ED is possible; however, it needs 
to be governed by the composition of the whole formulation. 
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1. Introduction 
Nowadays, we are faced with the rapid development of three-dimensional (3D) 
printing techniques in pharmaceuticals. Three-dimensional printing brings unprece-
dented opportunities to individualize medicine to a patient’s body weight and lifestyle 
by dose and dosage form adjustment [1]. Various 3D printing technologies have been in-
tensively investigated in the past decade in pharmaceutical fields, such as fused filament 
fabrication (FFF), stereolithography (SLA), digital light processing (DLP), selective laser 
sintering (SLS) and 3D inkjet printing [2–4]. 
SLS is a rapid prototyping technique for the production of 3D objects through selec-
tively sintering powder-based layer materials [2,5,6]. During the printing process, the la-
ser is directed to draw a specific pattern onto the surface of the powder bed. Once the first 
layer is completed, the powder bed moves down to the z-axis, the reservoir moves up and 
a roller distributes a new layer of powder on top of the previous one [7]. The process is 
repeated many times until the desired object is created. The method is solvent free and 
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does not require a filament form of raw material or photopolymerizable resin. Addition-
ally, there is no requirement for the addition of liquid binder [7,8]. The main disadvantage 
of SLS technology is that it requires a high temperature; thus, SLS printing is appropriate 
for thermostable substances. In order to obtain the dosage form of the desired character-
istics, it is necessary to understand the printing process from the choice of material to the 
characteristics of the final form. 
The most commonly used excipients in SLS printing of dosage forms are lactose mon-
ohydrate [7,9,10], Kollidon®  VA 64 [10–12], Kollicoat®  IR [5], hydroxypropyl methylcellu-
lose [12], ethyl cellulose [8,13] and Eudragit®  L100-55 [5,13]. Particles should have good 
flow properties and optimum size and shape [14,15]. The recommendation for the optimal 
SLS printing process is that the particle size should be from 58 to 180 µm [6]. In the litera-
ture, there is a limited number of studies in the pharmaceutical field characterizing the 
properties of powder mixtures in SLS printing. They were mostly based on an investiga-
tion of their thermal characteristics. Thakkar et al. characterized powder flow and the an-
gle of response for tested formulations [16]. 
The development of drug-delivery devices by SLS has been conducted using biode-
gradable and biocompatible polymers [17–21]. According to a recent published review 
paper, fourteen publications on SLS applied to pharmaceutical research on solid oral 
forms were identified in the MEDLINE®  database from 2017 to 2020 [15]. The first report 
on the use of SLS in the preparation of oral dosage forms was in 2017, and it explored the 
drug release properties of printed tablets [5]. Studies are, then, geared towards the devel-
opment of orally disintegrating printlets [12,22], drug-loaded gyroid lattices [13], mini-
printles [8], printlets with braille and moon patterns [23], amorphous solid dispersion dos-
age forms [24] and high-dose controlled release pharmaceutical dosage forms [25]. A re-
cent study combined the application of twin-screw granulation and selective laser sinter-
ing 3D printing for the development of pharmaceutical dosage forms with enhanced dis-
solution rates and physical properties [16]. The obtained dosage forms were characterized 
in terms of solid-state and morphological characteristics, mechanical properties, drug con-
tent, disintegration time and drug release testing. 
Laser power, bed temperature, and layer thickness are recognized as the most im-
portant process parameters which affect the quality of produced objects [26]. In a study 
by Fina et al., the possibility of modulating drug release properties with different laser 
speeds was demonstrated [12]. In a study by Barakh Ali et al., the formulation and process 
variables affecting the quality of the printlets were investigated using the Box–Behnken 
response surface methodology [10]. Response surface methodology was also used for the 
optimization of formulations [7]. Energy density (ED) could be considered a critical pa-
rameter in SLS printing [15]. ED is the amount of energy transmitted per volume unit [27]. 
It depends on four process parameters and it could help standardize the interpretation of 
the results between different printers [15]. 
Irbesartan, the model drug in this study, is used for the treatment of hypertension 
and belongs to Class II drugs according to the Biopharmaceutical Classification System 
(BCS); i.e., it has low solubility and high permeability. Irbesartan was used as one of the 
five drugs in the production of SLA 3D multi-layer antihypertensive polypill [28] and this 
is the first time it has been applied in SLS 3D printing. 
A recently published study showed that photo-absorber loading and ED could be 
critical for printing efficiency and dimensional accuracy [29]. Printability, an important 
aspect for understanding the sintering process has been evaluated in one article, and the 
need for more detailed research has been recognized [15]. The main purpose of this man-
uscript was to investigate the effect of ED and formulation factors on printability using a 
decision tree as a data mining tool, and then to evaluate the effects of these factors on the 
characteristics of the produced SLS irbesartan tablets. 
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2. Materials and Methods 
2.1. Materials 
Irbesartan, a model active substance, was donated by Hemofarm (Vrsac, Serbia). Lac-
tose monohydrate was purchased from CARLO ERBA (Milan, Italy). Vivapharm®  E3, (hy-
droxypropylmethylcellulose, HPMC) was obtained from JRS Pharma (Rosenberg, Ger-
many). Mannitol Parteck®  M 200 and Candurin®  Gold Sheen were obtained from Merck, 
Darmstadt, Germany. Kollidon®  VA 64 Fine (vinylpyrrolidone-vinyl acetate copolymer) 
was supplied from BASF, Ludwigshafen, Germany. Crospovidone NF (Polyplasdone®  
XL-10) was obtained from Ashland (Wilmington, DE, USA) and AEROSIL®  200 (colloidal 
silicon dioxide) was provided by Evonik (Essen, Germany). 
2.2. Methods 
2.2.1. Preparation of Powder Blends 
Different formulations prepared for 3D printing are shown in Table 1. Candurin®  
Gold Sheen was added to enhance energy absorption from the laser and to aid printability 
in the SLS process [12]. Formulations FM1 and FM2 contained mannitol, whereas formu-
lations FH1–FH8 contained HPMC as the excipient, which is present in the largest per-
centage. In formulations FH2, FH3, FH4 and FH8, crospovidone, as a super disintegrant, 
was added to increase the disintegration time which would allow for a faster drug release. 
FH5 contained Kollidone®  VA 64 Fine, whereas FH6, FH7 and FH8 contained lactose mon-
ohydrate to investigate their effects on the printability and characteristics of tablets. For 
all the formulations, 150 g of a mixture containing a drug and excipients were blended in 
a powder mixer (Farmalabor, Canosa di Puglia, Italy) for 9 min at 60 rpm. Afterward, 
colloidal silicon dioxide (1% w/w) was added, and the powder was mixed for an additional 
one minute. 
Table 1. Composition (% w/w) of the initial formulations. 
 FM1 FM2 FH1 FH2 FH3 FH4 FH5 FH6 FH7 FH8 
Irbesartan 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Candurin Gold Sheen 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 
Silicon dioxide 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Mannitol 81.0 81.0 - - - - - - - - 
HPMC - - 91.0 90.0 89.0 86.0 71.0 46.0 71.0 69.0 
Crospovidon - - - 1.0 2.0 5.0 - - - 2.0 
Kollidon VA 64 Fine - 10.0 - - - - 20.0 - - - 
Lactose monohydrate 10.0 - - - - - - 45.0 20.0 20.0 
2.2.2. Characterization of Powder Blends 
Particle Size Distribution 
Particle size distribution was analyzed by sieving using a vibrating shaker (ERWEKA 
AR400, Heusenstamm, Germany) and six standard sieves in the range of 45–500 µm. The 
sample mass was 100.00 g. The amount of material that remained on each sieve was accu-
rately weighted to determine the particle size distribution of HPMC, mannitol, lactose 
monohydrate and each formulation. 
Powder Flow Properties 
The flowability of powder was measured by the indirect method, determining the 
bulk and tapped densities according to the Ph. Eur. 10.0 recommendations, and by calcu-
lating the Hausner ratio and compressibility index (CI). The volumeter STAV 2003 (J.En-
gelsmann AG, Ludwigshafen , Germany) was used to determine the tapped density. The 
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Hausner ratio and CI were calculated using Equations (1) and (2), respectively, as below 
(Ph. Eur. 10.0): 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑟𝑎𝑡𝑖𝑜 =
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦     
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 (1) 
𝐶𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 (𝐶𝐼) =
(𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 − 𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
× 100  (2) 
The flowability characteristics of the powders was defined following descriptive 
terms given in Ph. Eur. 10.00. 
2.2.3. Preparation of Tablets 
Selective Laser Sintering 3D Printing 
A 3D model of the printed dosage forms (a cylinder 6 mm in diameter, and 3 mm in 
height) was designed with Autodesk Fusion 360 software version 2.0.8809 (Autodesk Inc., 
San Rafael, CA, USA) and exported as a stereolithography file (.stl) into the 3D printer 
software (Sintratec Central, version 1.2.0, Sintratec Kit, AG, Brugg, Switzerland). The 
blend was filled in the modified powder reservoir compartment of the SLS printer (Sin-
tratec Kit, AG, Brugg , Switzerland) equipped with a 2.3 W 455 nm laser. A powder batch 
of 100 g was used for each build cycle. The printing parameters were controlled using 
Sintratec 3D printer software. For each formulation, the printing was tested under differ-
ent conditions through varying printing temperatures, laser speeds and layer heights, af-
ter which the parameters of successful printing were selected (Table 2). Hatch spacing was 
set at 250 µm. The chamber temperature was kept below the surface temperature for en-
suring the proper transfer of the physical mixture to the print chamber [24]. The obtained 
SLS tablets from the same formulation but with different laser speeds, were marked with 
P1, P2, etc. Energy density (ED) is the amount of energy transmitted per volume unit. It 
depends on four process parameters and could be considered a critical parameter in SLS 
printing [15]. ED was calculated by Equation (3). 
𝐸𝐷 =
𝐿𝑃
𝑆𝑆 × 𝐿𝑆 × 𝐻𝑆
 (3) 
where LP, SS, HS and LT are, respectively, laser power, scanning speed, hatch spacing and 
layer thickness. The laser power in the printer used in this study, the Sintratec Kit, is not 
tunable. Hatch spacing was kept constant. Layer height was adjusted to the particle size. 
The evaluation of ED as critical process parameters in the SLS printing of solid dosage 
forms could allow for the comparison of the results between different printers. Hence, in 
this work, ED was studied through a change in laser speed. 
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Table 2. SLS printing parameters for printing irbesartan SLS tablets. 
Formulation 















FM1 150.00 160.00 60.00 200.00 0.77 
FM2 125.00 140.00 50.00 200.00 0.92 
FH1 P1 140.00 155.00 100.00 100.00 0.92 
FH1 P2 140.00 155.00 120.00 100.00 0.77 
FH1 P3 140.00 155.00 140.00 100.00 0.66 
FH1 P4 140.00 155.00 160.00 100.00 0.57 
FH2 P1 140.00 155.00 100.00 100.00 0.92 
FH2 P2 140.00 155.00 120.00 100.00 0.77 
FH2 P3 140.00 155.00 140.00 100.00 0.66 
FH3 P1 140.00 155.00 100.00 100.00 0.92 
FH3 P2 140.00 155.00 120.00 100.00 0.77 
FH3 P3 140.00 155.00 140.00 100.00 0.66 
FH3 P4 140.00 155.00 160.00 100.00 0.57 
FH4 P1 140.00 155.00 100.00 100.00 0.92 
FH4 P2 140.00 155.00 120.00 100.00 0.77 
FH4 P3 140.00 155.00 140.00 100.00 0.66 
FH4 P4 140.00 155.00 160.00 100.00 0.57 
FH4 P5 140.00 155.00 180.00 100.00 0.51 
FH4 P6 140.00 155.00 220.00 100.00 0.42 
FH5 P1 115.00 120.00 100.00 100.00 0.92 
FH5 P2 115.00 120.00 120.00 100.00 0.77 
FH6 130.00 140.00 100.00 200.00 0.46 
FH7 P1 140.00 155.00 100.00 100.00 0.92 
FH7 P2 140.00 155.00 120.00 100.00 0.77 
FH8 P1 140.00 155.00 100.00 100.00 0.92 
FH8 P2 140.00 155.00 120.00 100.00 0.77 
FH8 P3 140.00 155.00 140.00 100.00 0.66 
2.2.4. Decision Tree Modelling 
Applying a decision tree has been proved to be an effective and reliable technique 
[30]. It mimics human decision making and it can be easily visualized in the form of a tree, 
making it easy to convey and interpret results [31]. In order to better understand the print-
ability of prepared HPMC physical mixtures, RapidMiner Studio software version 9.9 
(RapidMiner Inc., Boston, MA, USA) was used. The input data used to generate the deci-
sion tree were the following: ED, particle size distribution, the content of crospovidone, 
HPMC, Kollidon®  VA 64 Fine and lactose monohydrate. Printability (categorized as yes 
and no) was set as a target role. The data were split between training (70%) and test dataset 
(30%). The minimal leaf size varied from 1 to 5, a minimal gain from 0.01 to 0.05. A maxi-
mal tree depth from 5 to 10 was used in the study in order to obtain a decision tree with 
the best accuracy. The optimal combination of parameters is determined by trying out all 
possibilities. Accuracy was calculated as a percentage of correct predictions. A pruning 
technique (pre-pruning and post-pruning) was used for preventing the overfitting of the 
data. A confidence level of 0.1 was selected for the pessimistic error calculation of pruning. 
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2.2.5. Characterization of the Tablets 
Determination of the Physical and Mechanical Properties 
Tablets (n = 10) were weighed on a Sartorius BP 210 D analytical balance (Sartorius, 
Goettingen, Germany) and measured (diameter and thickness) using a digital caliper (Vo-
gel, Kevelaer, Germany). The breaking force of the tablets (n = 10) was measured using 
the ERWEKA TBH 125D (ERWEKA, Langen, Germany), a hardness tester. 
Mercury Intrusion Porosimetry (MIP) Measurements of Irbesartan Tablets 
MIP measurements were performed in a fully automated conventional apparatus, 
the CARLO ERBA Porosimeter 2000 (Carlo Erba, Milan, Italy), pressure range: 0.1–200 
MPa; pores with a diameter between 7.5 and 15,000 nm. The acquisition of the analysis 
data was performed using the Milestone Software 200 (Carlo Erba, Milan, Italy). Two sub-
sequent intrusion–extrusion runs (Run I and Run II) were conducted. The samples were 
evacuated for 2 h in a dilatometer placed in the Macropores Unit 120. 
Scanning Electron Microscopy (SEM) 
The morphology of the tablets’ cross-sections was investigated using SEM. Samples 
were coated with gold alloy at 30 mA for 100 s on the BAL-TEC SCD 005 sputter coater 
(Leica Microsystems, Wetzlar Germany) to improve their conductivity during recording. 
Micrographs were taken with the JEOL JSM-6390LV scanning electron microscope (JEOL, 
Tokyo, Japan) at suitable magnifications. 
Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR spectra of raw materials and crushed tablets were recorded using the Nicolet 
iS10 (Thermo Scientific, Waltham, MA, USA) FT-IR spectrometer, equipped with a single 
reflection ATR system (Smart iTR, Thermo Scientific, Waltham, MA, USA) with a dia-
mond plate and ZnSe lens. The spectra were collected as an average of 16 scans in the 
frequency range from 4000 to 650 cm−1, with a resolution of 2 cm−1. 
Differential Scanning Calorimetry (DSC) 
In this study, DSC was used to investigate the physical state of the drug in the for-
mulations. DSC analyses were performed on a Mettler Toledo AG DSC 1 differential scan-
ning calorimeter (Analytical, Zurich, Switzerland). Accurately weighed 5–10 mg samples 
were placed in pierced aluminum pans and subjected to heating at 10 °C/min in the range 
from 25–250 °C under a nitrogen purge gas flow of 50 mL/min. An empty pan was used 
as a reference. 
2.2.6. Disintegration 
The tablets’ disintegration time was measured according to the Ph. Eur. 10.0 proce-
dure, in a compendial ERWEKA ZT 52 disintegration tester (Erweka GmbH, Langen, Ger-
many), using 800 mL of purified water as media at 37 ± 0.5 °C. One tablet was placed in 
each of the six tubes of the basket, and covered with a disc. 
2.2.7. Drug Content 
Tablets (n = 3) were crushed using a mortar and pestle. Approximately 100 mg was 
diluted with 10 mL methanol. Samples were placed in a Bandelin Sonorex RK102H ultra-
sonic bath (Bandelin Sonorex, Berlin, Germany) at room temperature and sonicated for 15 
min to enhance the extraction of irbesartan. After filtration, 1 mL of the solution was di-
luted with 0.1 M HCl. The amount of drug in the solution was determined UV spectro-
photometrically using the Evolution 300 (Thermo Fisher Scientific, Waltham, MA, USA) 
at 225 nm. Because no excipients are absorbed at the same wavelength as irbesartan, UV 
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spectrophotometry was used as the method of choice. The measurement was done in trip-
licate. The obtained drug content was expressed as a percentage of the theoretical drug 
content ± standard deviation (S.D.). 
2.2.8. Dissolution and Drug Release Analysis 
Drug dissolution profiles for the 3D tablets were obtained with the paddle apparatus 
ERWEKA DT 600 (Erweka GmbH, Langen, Germany) in 500 mL of 0.1 M HCl at 37 ± 0.5 
°C with a paddle speed of 50 rpm. Samples were withdrawn at a predetermined time 
interval and the absorbance of the dissolved irbesartan was measured UV spectrophoto-
metrically at the wavelength of the relative maximum absorbance of irbesartan (225 nm). 
The analysis was performed in triplicate. FH8 P1, P2 and P3 tablets exhibited floating 
characteristics and they were investigated in the basket apparatus in 500 mL 0.1 M HCl at 
37 ± 0.5 °C, with the rotation speed of 100 rpm. This speed is discriminatory for the basket 
method [32]. 
Therefore, drug release profiles were fitted into four mathematical models including 
zero-order, first-order, Higuchi, and Korsmeyer–Peppas. 
3. Results 
3.1. Characterization of Powder Blends 
The particle size from 58 to 180 µm and good flowability characteristics are described 
as optimal for the SLS printing process [6]. Guided by this, powders with poor flow char-
acteristics were excluded from the study and the data are not shown. Mannitol (Parteck®  
M 200) was chosen because of its unique surface structure, and HPMC was chosen because 
of its printable properties which have previously been described in the literature. Addi-
tionally, mannitol and HPMC have melting temperatures (165 °C and 160 °C, respectively) 
that are within the operating range of the SLS printer. The particle size distribution is 
shown in Figure 1. It can be observed that in formulations FM1 and FM2, the most com-
mon are particles 250–500 µm in size. In other formulations, the most common are parti-
cles 65–250 µm in size. These results are in accordance with the particle size distribution 
of mannitol and HPMC. 




Figure 1. Particle size distribution of powder mixtures for 3D printing. 
From the results in Table 3, it can be concluded that formulation FM1 had fair flow 
characteristics, whereas FM2 had good flow characteristics. They had better flowability 
than other formulations due to the presence of mannitol obtained in the spray granulation 
process. All other formulations had passable flow characteristics, except FH8, which had 
poor flow characteristics. According to the results, FM1 and FM2 were not printable due 

























9.73 15.16 47.94 26.42 0.75 0.00 0.00
Mannitol
1.92 2.54 19.43 26.91 29.73 18.12 1.35
Lactose monohydrate
2.05 32.71 46.42 12.32 3.70 0.23 2.57
FM1
0.14 1.14 6.36 10.70 27.19 53.38 1.08
FM2
0.08 2.06 12.38 19.25 27.69 35.67 2.86
FH1
3.23 12.43 50.05 29.98 4.31 0.00 0.00
FH2
2.17 10.12 32.26 31.76 19.57 4.12 0.00
FH3
0.15 5.58 43.15 42.75 7.84 0.53 0.00
FH4
0.00 0.61 14.33 43.96 31.88 9.21 0.00
FH5
15.73 17.53 53.70 12.53 0.34 0.17 0.00
FH6
0.30 0.86 7.07 24.84 51.18 14.97 0.00
FH7
0.44 4.23 29.88 34.01 23.49 7.95 0.00
FH8
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material and the definition of its desirable characteristics have been recognized as the 
greatest challenges in SLS printing [7]. Insufficient information on the use of pharmaceu-
tical excipients in SLS printing creates a need for detailed investigation. In this study, 
HPMC E3 proved to be an excellent excipient for SLS printing. However, for better un-
derstanding the printability of HPMC physical mixtures, a data mining tool was used and 
is described further in the text. 
Table 3. Physical and mechanical properties of irbesartan tablets. 
Formulation 

















FM1 n.d. n.d. n.d. n.d. n.d. 1.24 19.35 n.d. 
FM2 n.d. n.d. n.d. n.d. n.d  1.14 12.5 n.d. 
FH1 P1 35.1 ± 6.3 5.4 ± 0.1 2.6 ± 0.3 1510.0 56.0 ± 11.3 
1.28 22.38 
99.0 ± 0.9 
FH1 P2 42.3 ± 8.1 5.15 ± 0.1 3.4 ± 0.3 1140.0 35.0 ± 31.1 100.5 ± 1.4 
FH1 P3 44.7 ± 6.4 5.5 ± 0.1 3.4 ± 0.1 840.0 27.0 ± 10.5 101.9 ± 4.6 
FH1 P4 44.0 ± 6.4 5.3 ± 0.3 3.5 ± 0.1 690.0 30.3 ± 11.1 99.6 ± 1.4 
FH2 P1 32.2 ± 5.6 5.3 ± 0.2 2.8 ± 0.4 1000.0 51.0 ± 2.8 
1.32 24.56 
86.9 ± 0.7 
FH2 P2 39.5 ± 8.3 5.2 ± 0.2 3.6 ± 0.4 720.0 48.3 ± 12.1 96.4 ± 1.0 
FH2 P3 37.1 ± 8.5 5.3 ± 0.2 3.4 ± 0.3 460.0 n.d. 99.1 ± 2 
FH3 P1 35.8 ± 4.1 5.5 ± 0.2 2.7 ± 0.4 660.0 45.3 ± 10.2 
1.31 23.00 
104.6 ± 0.5 
FH3 P2 29.5 ± 6.5 5.4 ± 0.2 2.6 ± 0.2 500.0 n.d. 102.3 ± 3.1 
FH3 P3 29.4 ± 6.7 5.4 ± 0.1 2.5 ± 0.3 380.0 n.d. 96.2 ± 2.3 
FH3 P4 34.3 ± 4.4 5.3 ± 0.1 3.2 ± 0.2 420.0 n.d. 94.6 ± 3.2 
FH4 P1 36.3 ± 6.5 5.4 ± 0.1 2.6 ± 0.5 1220.0 55.7 ± 15.3 
1.31 23.7 
89.2 ± 1.0 
FH4 P2 26.7 ± 8.6 5.0 ± 0.2 2.0 ± 0.4 1040.0 27.7 ± 14.6  95.5 ± 3.3 
FH4 P3 40.4 ± 9.1 5.3 ± 0.1 3.3 ± 0.3 960.0 51.0 ± 19.1 95.4 ± 2.9 
FH4 P4 30.5 ± 7.2 5.3 ± 0.2 3.0 ± 0.3 600.0 n.d. 94.4 ± 0.1 
FH4 P5 38.3 ± 5.7 5.1 ± 0.2 3.4 ± 0.2 540.0 n.d. 92.2 ± 0.9 
FH4 P6 27.8 ± 10.2 5.0 ± 0.3 2.6 ± 0.5 480.0 n.d. 94.7 ± 0.5 
FH5 P1 46.6 ± 12.3 5.4 ± 0.2 4.2 ± 0.4 1105.0 48.3 ± 14.1 
1.29 22.49 
107.2 ± 0.5 
FH5 P2 43.8 ± 5.9 5.2 ± 0.5 4.2 ± 0.3 488.0 15.7 ± 2.1 113.0 ± 0.1 
FH6 26.2 ± 7.1 5.3 ± 0.3 2.8 ± 0.2 240.0 n.d. 1.31 23.88 91.37 ± 0.5 
FH7 P1 41.5 ± 6.7 5.5 ± 0.1 3.1 ± 0.0 780.0 n.d. 
1.28 21.88 
106.7 ± 6.5 
FH7 P2 27.6 ± 7.2 5.0 ± 0.5 3.0 ± 0.6 220.0 n.d. 100.7 ± 2.9 
FH8 P1 40.2 ± 7.2 5.6 ± 0.2 3.2 ± 0.3 260.0 12.5 ± 2.1 
1.36 26.91 
105.6 ± 7.9 
FH8 P2 36.96 ± 6.3 5.5 ± 0.2 3.1 ± 0.2 180.0 n.d. 109.3 ± 0.6 
FH8 P3 28.6 ± 3.9 5.4 ± 0.2 3.2 ± 0.2 90.0 n.d. 105.9 ± 5.2 
n.d.-not determined. 
3.2. Preparation of Tablets 
The biggest challenge with the SLS printing was finding appropriate printing param-
eters. In most studies, there are only reports on the temperature used without any details 
on how the temperature was determined. The literature suggests that the powder bed 
temperature should be set at least 3–4 °C lower than their melting point or close to their 
glass transition temperature [6]. Moreover, the chamber temperature should be set below 
the surface temperature [24]. Printing parameters were investigated with a trial and error 
approach. Parameters were considered unsuitable when the obtained tablets became 
darker and burned on the surface. Further attempts were made with lower temperatures 
and higher laser speeds. If tablets disintegrated in the hand upon removal from the cham-
ber, the printing parameters were also considered unsuitable. After selecting the success-
ful printing parameters, tablets were printed with an SLS printer (Figure 2). During one 
print, it was possible to print up to ten tablets, and the time required for printing one set 
of tablets was 17 min and 51 s. All tablets in one print were successfully printed. 




Figure 2. Photographs of the selected SLS-printed tablets with irbesartan. Tablets were printed with 
different laser speeds. From left to right: 100.00 mm/s, 120.00 mm/s, 140.00 mm/s, 160.00 mm/s, 
180.00 mm/s, and 220.00 mm/s. 
3.3. Decision Tree 
The printability of pharmaceutical materials is influenced by formulation character-
istics as well as process conditions [15]. The printability of raw materials, including drugs 
and excipients, was evaluated in a study conducted by Yang et al. [29]. The authors eval-
uated photo-absorber loading and energy density (ED) on printing efficiency and dimen-
sional accuracy. In this study, decision tree modeling was used to understand the printa-
bility factors of physical mixtures with HPMC for SLS printing. A decision tree was de-
veloped by testing several values for minimal leaf size, minimal gain and maximal tree 
depth and selecting the tree with the best accuracy. The decision tree model ran with a 
minimal leaf size of 2 and a minimal gain of 0.01 to produce a split, and a maximal tree 
depth of 10 achieved the best overall accuracy of 80.00%. A created decision tree is pro-
vided in Figure 3. It demonstrated how printability is affected by both formulation and 
ED. The most important factor that affected printability was the content of crospovidone. 
If the content of crospovidone is greater than 3.5%, the formulation is printable. If the 
content is less than 3.5%, then it is important to consider the ED. If the ED is less than 0.615 
J/mm3, then the formulation is not printable. Otherwise, it is necessary to consider the 
content of HPMC. Results suggest that a decision tree could be a useful tool in under-
standing the SLS printability of pharmaceutical materials. Decision trees are powerful 
classification algorithms that are used in medicine and other areas [30,33–35]. Decision 
trees have been also used to analyze the printability of filaments in the FDM technique 
[36] but there is no literature data on the application of decision tree methodology in SLS 
printing. Created decision trees can be used for predicting printability instead of usage in 
a trial-and-error approach, which is both time- and resource-consuming. Similar to most 
machine learning algorithms, the employed methodology is data-dependent. Further in-
vestigation with larger data sets could be a step forward in the optimization of formula-
tion and process development of SLS printing. 




Figure 3. Decision tree for SLS printability of powder mixtures with irbesartan. 
3.4. Effect of Formulation Factors on Printability 
In a study by Allahham et al., Mannitol Parteck®  Delta M was used as a filler for the 
production of SLS orally disintegrated tablets [22]. In this study, Mannitol Parteck®  M 200 
was used, although formulations FM1 and FM2 could not be considered printable because 
the tablets achieved very poor mechanical characteristics and they disintegrated in the 
hand upon removal from the chamber. The next choice was HPMC due to its melting 
temperature (160 °C) that is within the operating range of the SLS printer. HPMC has 
shown appropriate characteristics for SLS printing, and all FH formulations were printa-
ble. For the first time, crospovidone was used for SLS printing. It was added as a super 
disintegrant, but due to the melting temperature (150 °C) which is close to the printing 
temperature, a more efficient sintering process occurred and sintering was enabled at dif-
ferent laser speeds. Formulation FH4 (crospovidone 5%) was printable with a wide range 
of laser speeds (laser speeds from 100.00 to 220.00 mm/s), hence it was possible to evaluate 
the effects of laser speed on tablet characteristics. The FH6 (lactose monohydrate 45%) 
formulation was printable only with 100.00 mm/s; with laser speeds of 120.00 mm/s and 
faster, the tablets had very poor mechanical characteristics and they were excluded from 
the study. Formulation FH7 (lactose monohydrate 20%) was printable with a laser speed 
of 100.00 to 120.00 mm/s. It was reported that the SLS tablets containing a high lactose 
monohydrate concentration required high energy (slow laser scanning speed and high 
chamber temperature) to sinter/melt the powder [10]. In addition, lactose monohydrate 
has a higher melting temperature than polymer. Hence, it can be concluded that the en-
ergy transmitted to FH6 and FH7 formulations with a higher laser speed was not suffi-
cient. The formulation FH8 (lactose monohydrate 20%) contained 2% crospovidone, in 
addition to lactose monohydrate and was printable with laser speeds up to 140.00 mm/s. 
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3.5. Characterization of the Tablets 
3.5.1. Physical and Mechanical Properties of Irbesartan Tablets 
The physical and mechanical properties of irbesartan tablets are summarized in Table 
3. It was observed that tablets printed with a slower laser speed tend to be heavier (Figure 
4) because powder particles are subjected to higher ED, empty spaces are reduced and 
there is more room for powder particles to be sintered [12]. This effect of ED on the weight 
of the tablets could be observed in tablets from formulations with Kolidon VA64 (FH5) 
and lactose monohydrate (FH7 and FH8; one type of tablet was printed from FH6). For 
most of the SLS tablets, the breaking force was too low to be detected. This is particularly 
noticeable in tablets with lactose monohydrate. The negative effect of lactose monohy-
drate on hardness is reported in the literature [10]. 
 
Figure 4. Effect of energy density on the disintegration time and weight of FH8 SLS tablets. 
3.5.2. MIP Measurements of Irbesartan Tablets 
MIP measurements of FH8 P1, P2 and P3 irbesartan tablets (n = 3) are given in Table 
4 and pore size distribution (PSD) is shown in Figure 5. During the first Hg intrusion cycle, 
mercury filled up both the interparticle (voids) and intraparticle spaces, whereas in the 
second cycle of the measurement, Hg could occupy only the space of the accessible pores 
(intraparticle space) [37]. The porosity for FH8 P1, P2 and P3 in the second run was de-
creased by >60%. That reduction indicates the presence of a specific pore shape, as well as 
interparticle porosity. Analyzed samples were found to belong to the group of highly 
macroporous materials. These results are confirmed by SEM micrographs, on which a 
macroporous structure can be seen. In FH8 P3 tablets, the porosity was about 28.5% of the 
total value obtained in the first run, leading to the conclusion that more voids between 
particles were present in FH8 P3 than in FH8 P1 and P2. 













I 0.17 28.00 8.00 1.07 18.40 
II 0.06 7.60 10.00 1.07 6.50 
FH8 P2 
I 0.13 13.40 8.00 1.14 15.00 
II 0.05 10.10 8.00 1.14 5.50 
FH8 P3 
I 0.15 17.80 0.01 1.14 16.50 
II 0.04 5.60 0.01 1.14 4.70 
















































Figure 5. Pore size distribution curves of SLS tablets (a) FH8 P1, (b) FH8 P2, and (c) FH8P3. 
3.5.3. SEM 
The SEM images provided the morphological properties of the tablets (Figure 6). It 
can be seen on the SEM micrographs of SLS tablets that some parts are sintered, whereas 
substance remained in the powder form (Figure 6a–c). These structures create tablets with 
interparticle pores, although liquid can penetrate quickly, resulting in the rapid disinte-
gration of the tablets. Increasing the laser speed and reducing the ED results in the reduc-
tion of the powder particles’ sintering and, consequently, the formation of more interpar-
ticle pores (voids) occurs [12]. A faster laser speed (140.00 mm/s) for FH8 P3 tablets led to 
an increase in voids between particles when compared with FH8 P2 and P1, which printed 
at 120.00 mm/s and 100.00 mm/s, respectively. 







Figure 6. SEM micrographs of the cross-sectional view of irbesartan tablets (a) FH8 P1, (b) FH8 P2, and (c) FH8 P3. 
3.5.4. FT-IR 
Crystalline irbesartan shows characteristic absorption bands at 1730 and 1620 cm−1, as-
signed to the carbonyl moiety of the carboxyl group and the C=N bond in the diazaspiro 
ring vibrations, respectively (Figure 7). These values are similar to those reported by 
Skotnicki et al. (1733 and 1617 cm−1) and Yan et al. (1732 and 1616) [38,39]. The FT-IR 
spectrum of HPMC displays a peak at 3450 cm−1, revealing the presence of hydroxyl 
group (OH) stretching. The bend at around 2960 cm−1 is attributed to the single bond C-
H stretching [40] and the intense peak at 1060 cm−1, and represents out-of-phase vibra-
tions associated with an alkyl-substituted cyclic ring containing ether linkages [41,42]. 
The lactose monohydrate band corresponding to the hydroxyl group (O-H) is a broad 
peak at 3280 cm−1. It also exhibited the characteristic doublet peaks at 1070 and 1030 
cm−1, corresponding to skeletal vibrations of C-C stretching. These results are verified in 
a study conducted by Barakh Ali et al. (2019). Crospovidone shows a sharp peak at 1270 
cm−1 due to C-N stretching, following a literature study performed by Jana et al. (2014) 
[43]. In the case of the FH8 physical mixture and FH8 P2 characteristics, peaks of irbesar-
tan were observed. Therefore, the FT-IR analyses indicated the absence of any significant 
interaction between the irbesartan and the excipients used. 




Figure 7. FT-IR spectra of raw materials and evaluated tablet formulations. 
3.5.5. DSC 
In this study, DSC was used to verify the physical state of the drug in the formula-
tions (Figure 8). The DSC curve of pure irbesartan exhibited single endothermic peaks at 
185.67 °C, which is designated as the melting point of the irbesartan [44,45]. All evaluated 
formulations as well as the FH8 physical mixture showed broad endotherm correspond-
ing to the water evaporation and polymer relaxation [12,46]. The FH8 physical mixture 
and FH8 P2 formulations containing lactose monohydrate showed an endothermic peak 
at 218–230 °C, which refers to the lactose melting [47]. In the FH3, FH5 and FH8 physical 
mixtures, a small endothermic peak at 181–186 °C is evident, suggesting the presence of 
irbesartan in crystalline form. No endothermic peak near 185 °C was detected in tablets 
prepared with the SLS 3D printing method (FH3 P2, FH5 P2 and FH8 P2), indicating that 
irbesartan is present in an amorphous form. The amorphization of drugs from their crys-
talline state can enhance the dissolution and bioavailability of low solubility drugs (BCS 
Class II or IV) since the amorphous state is generally associated with higher solubility 
[48,49]. A few studies reported the improvement of irbesartan’s solubility by converting 
it into an amorphous form as well as by preparing solid dispersions [50,51]. The amor-
phous form of irbesartan in the SLS tablets can be attributed to a conversion induced by 
an elevated temperature and laser irradiation during the printing process [8]. The amor-
phization of the drug in SLS printing has been reported in the literature. In a study by 
Fina et al., the conversion of paracetamol from a crystalline to amorphous state was ob-
served in a mixture which also contained HPMC [12]. The presence of indomethacin in an 
amorphous form was observed in a study by Thakkar et al. on the granules obtained by a 
hot melt extrusion-based granulation process and SLS 3D printed tablets with these gran-
ules [16]. Moreover, the amorphous form of lopinavir in SLS printlets was detected in a 
study by Hamed et al. [9]. In this study, it was also shown that SLS could be used for the 
production of tablets with amorphous active substances. 





Figure 8. DSC curves of (a) selected physical mixtures and SLS irbesartan tablets, and (b) irbesartan and excipients. 
3.5.6. Disintegration Time 
The time required for SLS tablets to disintegrate varied from 90.00 s to 1510.00 s (Ta-
ble 3). The positive effect of ED on disintegration time was pronounced (Figure 4). With 
increasing laser speeds, a less energetic sintering process occurred during the printing 
process and particles in the tablets detached from each other more easily [12]. This is also 
reported in a study conducted by Mohamed et al. [7]. 
3.5.7. Drug Content 
The irbesartan content in all formulations was 85.00–115.00% of the theoretical con-
tent which indicates that there was no degradation of the drug during the sintering pro-
cess (Table 3). 
3.5.8. Dissolution and Drug Release Kinetics 
The dissolution profiles of SLS tablets are provided in Figure 9. The correlation be-
tween disintegration time and drug release was observed. Tablets with a disintegration 
time of less than 325 s released irbesartan in less than one hour. It can be observed that 
FH8 P1, P2, and P3 reached complete release in less than 30 min. In a study conducted by 
Fina et al., formulations with HPMC produced with a laser speed of 300 mm/s exhibited 
the shortest dissolution profile, with complete drug release at approximately 2 h [12]. With 
SLS printing technologies and the adaption of formulation and process parameters, it was 
possible to produce tablets with HPMC as the main polymer, with complete drug release 
in less than 30 min. 
  











Figure 9. Drug release from irbesartan SLS tablets produced with different laser speeds: P1-100.00 mm/s, P2-120.00 mm/s, 
P3-140.00 mm/s, P4-160.00 mm/s, P5-180.00 mm/s, and P6-220.00 mm/s; (a) FH1, (b) FH2, (c) FH3, (d) FH4, (e) FH5, (f) 
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3.5.9. Effect of Crospovidone on Drug Release 
The developed decision tree showed the importance of crospovidone in printability. 
Surprisingly, crospovidone did not act as a super disintegrant in SLS printed tablets. The 
disintegration behavior of compacts containing crospovidone is attributed to the shape-
memory characteristics of crospovidone [52]. Upon contact with water, crospovidone ab-
sorbs water via capillary action and regains its normal structure after releasing an amount 
of energy capable of breaking the tablet. The effect of crospovidone on SLS tablets was 
more complex. In Figure 10, drug release from tablets with the same laser speed and dif-
ferent concentrations of crospovidone is presented. It was observed that adding cro-
spovidone leads to a decrease in drug release from SLS tablets. In tablets produced with 
a laser speed of 140.00 mm/s, drug release was slightly increased with the addition of 
crospovidone. The effect of crospovidone on disintegration and dissolution has been ex-
tensively investigated, mostly on tablets prepared with conventional technologies. Not 
only did formulation factors have an influence, the effects of crospovidone are also gov-
erned by the manufacturing process [53–55]. Compression pressure is reported as an im-
portant parameter for consideration [56,57]. To the best of our knowledge, the usage of 
crospovidone in SLS printing has not been reported previously in the literature. The melt-
ing point of crospovidone is close to the printing temperature; therefore, the SLS printing 
process probably enabled the melting of crospovidone and a better sintering process, 
which led to a decrease in the disintegration properties of crospovidone and, conse-





Figure 10. Effect of crospovidone on drug release: (a) tablets printed with a laser speed of 100.00 mm/s; (b) tablets printed 























FH1 P1 krospovidon 0%
FH2 P1 krospovidon 1%
FH3 P1 krospovidon 2%
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FH1 P3 krospovidon 0%
FH2 P3 krospovidon 1%
FH3 P3 krospovidon 2%
FH4 P3 krospovidon 5%
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3.5.10. Tailoring Drug Release in SLS Printing 
The effect of laser speed and, consequently, ED as a process parameter on drug re-
lease is shown in Figure 9. Increasing drug release with increasing laser speed and de-
creasing ED was pronounced in tablets FH2 and FH3, and was also noticeable in FH1 and 
FH4. In these tablets, which were printed at 140.00 mm/s, the drug is released significantly 
faster than tablets printed at 100.00 mm/s. Tuning the drug release by the parameters of 
the SLS process (surface temperature and laser scanning speed) has been performed for 
immediate release tablets [10]. Additionally, a similar observation was concluded in a 
study by [12]. However, FH5 (Kollidon VA 64 Fine 20%) was printable at 100.00 and 120.00 
mm/s, and the effect of laser speed was not significant. In formulations containing HPMC 
and lactose monohydrate, SLS printing contributed to the production of voids through its 
medium and was able to penetrate fast, resulting in rapid drug release with a reduced 
impact of the laser speed. FH6 (lactose monohydrate 45%) was printable only with a laser 
speed of 100.00 mm/s. Complete release was reached in 30 min, but tablets had poor me-
chanical characteristics; thus, it was concluded that lactose monohydrate needed to be in 
a lower concentration. In tablets FH7 (lactose monohydrate 20%), a noticeable effect of 
laser speed on drug release was observed. However, laser speed did not have a significant 
influence on the drug release from FH8 P1, P2, and P3 tablets (lactose monohydrate 20% 
+ crospovidone 2%); moreover, they reached complete release in less than 30 min. Due to 
the presence of crospovidone, printing was possible with a wider range of laser speeds. 
The effect of laser speed and ED was manifested on the physical characteristics of the 
tablets (previously discussed) rather than drug release. Hamed et al. observed that in-
creasing the laser scanning speed from 75 to 100 mm/s, while keeping other variables con-
stant, had no significant effect on the drug dissolution rate from tablets consisting of 50% 
drug, 35.5% Kolicoat IR, 10% lactose monohydrate, 1.5 % talc and 3% Candurin®  NXT 
Ruby Red [9]. In conclusion, the tailoring of drug release in SLS printing might be 
achieved by formulation factors as well as process parameters, although it could be gov-
erned by the composition of the whole formulation. 
3.5.11. Drug Release Kinetics 
To interpret the mechanism of drug release, data were fitted into various kinetic 
models such as zero-order, first-order, the Higuchi equation, and the Korsmeyer–Peppas 
equation (Table S1). The highest R2 coefficient determines the suitable mathematical 
model that best describes drug release kinetics and exponent n gave insights into the 
mechanism of drug release [58,59]. The most proper model fitted to data based on having 
the closest R2 to 1 was the Higuchi model for tablets from FH1, FH3, FH4 and FH5 formu-
lations and Korsmeyer–Peppas for FH2, FH6, FH7 and FH8 formulations, but with very 
high values of R2 for the Higuchi model. Predominately, values for the exponent n were 
in the range from 0.45 to 0.89, indicating the combined drug release mechanisms of diffu-
sion and erosion, or the so-called anomalous transport mechanism [60]. 
4. Conclusions 
SLS is a challenging technique in terms of material selection and process parameters. 
It was observed that the printability of pharmaceutical powder mixtures was influenced 
by formulation characteristics and process conditions. The evaluation of energy density 
as critical process parameters in the SLS printing of solid dosage forms could allow the 
comparison of the results between different printers. This study demonstrated that deci-
sion tree methodology could be useful in understanding SLS printability. The most im-
portant factors that affected printability, according to the developed decision tree, were 
the content of crospovidone and ED. Tailoring tablets’ characteristics in SLS printing 
might be achieved by formulation factors as well as process parameters, although it needs 
to be governed by the composition of the whole formulation. The positive effect of ED on 
weight and disintegration time was observed; however, the impact of ED on drug release 
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was reduced in formulations with lactose monohydrate. By adjusting the formulation and 
process parameters, it was possible to produce SLS tablets of macroporous structure with 
amorphous irbesartan and HPMC as the main polymer with complete drug release in less 
than 30 min. The obtained results indicate the potential of SLS printing in the production 
of tablets, and represent a closer step towards understanding and optimizing the SLS 
printing process. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/pharmaceutics13111969/s1, Table S1: Parameters obtained by fitting dissolution data to 
various mathematical models 
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